Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Aclaris Therapeutics Inc. (ACRS) Insider Trading Activity
Healthcare • Diagnostics & Research • 86 employees
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Total Value
$1,226,192.08
Total Shares
995,010
Average Trade Value
$27,868.00
Most Active Insider
Mehra Anand
Total Activity: $1,499,999
Largest Single Transaction
$1,499,999
by Mehra Anand on Nov 19, 2024
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
CEO
|
Mar 1, 2025 | 3,277 | $6,521 | 1,466,907 (-0.2%) | Payment of Exercise Price | |
|
Chief Scientific Officer
|
Mar 1, 2025 | 27,258 | $54,243 | 265,662 (-10.3%) | Payment of Exercise Price | |
|
Chief Scientific Officer
|
Mar 1, 2025 | 10,925 | $10,000 | 292,920 (+3.7%) | Exercise/Conversion | |
|
Chief Scientific Officer
|
Mar 1, 2025 | 50,000 | $10,000 | 281,995 (+17.7%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Mar 1, 2025 | 1,100 | $10,000 | 90,960 (+1.2%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Mar 1, 2025 | 2,375 | $10,000 | 93,335 (+2.5%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Mar 1, 2025 | 727 | $1,447 | 92,608 (-0.8%) | Payment of Exercise Price | |
|
CEO
|
Mar 1, 2025 | 9,466 | $10,000 | 1,470,184 (+0.6%) | Exercise/Conversion | |
|
Chief Business Officer
|
Feb 1, 2025 | 11,250 | $10,000 | 96,503 (+11.7%) | Exercise/Conversion | |
|
Chief Business Officer
|
Feb 1, 2025 | 15,447 | $38,309 | 103,306 (-15.0%) | Payment of Exercise Price | |
|
Chief Financial Officer
|
Feb 1, 2025 | 14,750 | $10,000 | 95,676 (+15.4%) | Exercise/Conversion | |
|
Interim CEO
|
Feb 1, 2025 | 9,467 | $10,000 | 1,464,277 (+0.6%) | Exercise/Conversion | |
|
Chief Scientific Officer
|
Feb 1, 2025 | 11,317 | $28,066 | 231,995 (-4.9%) | Payment of Exercise Price | |
|
Interim CEO
|
Feb 1, 2025 | 3,559 | $8,826 | 1,460,718 (-0.2%) | Payment of Exercise Price | |
|
Chief Business Officer
|
Feb 1, 2025 | 7,500 | $10,000 | 104,003 (+7.2%) | Exercise/Conversion | |
|
Chief Business Officer
|
Feb 1, 2025 | 14,750 | $10,000 | 118,753 (+12.4%) | Exercise/Conversion | |
|
Chief Scientific Officer
|
Feb 1, 2025 | 7,500 | $10,000 | 228,562 (+3.3%) | Exercise/Conversion | |
|
Chief Scientific Officer
|
Feb 1, 2025 | 14,750 | $10,000 | 243,312 (+6.1%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Feb 1, 2025 | 5,816 | $14,424 | 89,860 (-6.5%) | Payment of Exercise Price | |
|
Chief Scientific Officer
|
Jan 2, 2025 | 17,380 | $10,000 | 229,976 (+7.6%) | Exercise/Conversion | |
|
Chief Business Officer
|
Jan 2, 2025 | 8,575 | $21,266 | 85,253 (-10.1%) | Payment of Exercise Price | |
|
Chief Financial Officer
|
Jan 2, 2025 | 5,059 | $12,546 | 80,926 (-6.3%) | Payment of Exercise Price | |
|
Interim CEO
|
Jan 2, 2025 | 29,149 | $10,000 | 1,468,342 (+2.0%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Jan 2, 2025 | 13,200 | $10,000 | 85,985 (+15.4%) | Exercise/Conversion | |
|
Interim CEO
|
Jan 2, 2025 | 13,532 | $33,559 | 1,454,810 (-0.9%) | Payment of Exercise Price | |
|
Chief Scientific Officer
|
Jan 2, 2025 | 8,914 | $10,000 | 221,062 (-4.0%) | Payment of Exercise Price | |
|
Chief Business Officer
|
Jan 2, 2025 | 18,150 | $10,000 | 93,828 (+19.3%) | Exercise/Conversion | |
|
Interim CEO
|
Jan 1, 2025 | 3,904 | $9,682 | 1,439,193 (-0.3%) | Payment of Exercise Price | |
|
Chief Financial Officer
|
Jan 1, 2025 | 2,430 | $6,026 | 72,785 (-3.3%) | Payment of Exercise Price | |
|
Interim CEO
|
Jan 1, 2025 | 9,467 | $10,000 | 1,443,097 (+0.7%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Jan 1, 2025 | 7,500 | $10,000 | 75,215 (+10.0%) | Exercise/Conversion | |
|
Chief Business Officer
|
Dec 31, 2024 | 32,089 | $79,581 | 75,678 (-42.4%) | Payment of Exercise Price | |
|
Chief Financial Officer
|
Dec 31, 2024 | 73,750 | $10,000 | 98,447 (+74.9%) | Exercise/Conversion | |
|
Chief Financial Officer
|
Dec 31, 2024 | 30,732 | $76,215 | 67,715 (-45.4%) | Payment of Exercise Price | |
|
Chief Business Officer
|
Dec 31, 2024 | 73,750 | $10,000 | 107,767 (+68.4%) | Exercise/Conversion | |
|
Chief Scientific Officer
|
Dec 31, 2024 | 32,937 | $10,000 | 212,596 (-15.5%) | Payment of Exercise Price | |
|
Chief Scientific Officer
|
Dec 31, 2024 | 73,750 | $10,000 | 245,533 (+30.0%) | Exercise/Conversion | |
|
Interim CEO
|
Dec 4, 2024 | 118,840 | $180,637 | 1,501,973 (+7.9%) | Exercise/Conversion | |
|
Interim CEO
|
Dec 4, 2024 | 68,343 | $256,970 | 1,433,630 (-4.8%) | Payment of Exercise Price | |
|
Interim CEO
|
Dec 1, 2024 | 9,466 | $10,000 | 1,385,854 (+0.7%) | Exercise/Conversion | |
|
Interim CEO
|
Dec 1, 2024 | 2,721 | $11,074 | 1,383,133 (-0.2%) | Payment of Exercise Price | |
| Nov 19, 2024 | 666,666 | $1,499,999 | 710,030 (+93.9%) | Purchase | ||
|
Interim President and CEO
|
Nov 1, 2024 | 2,721 | $5,687 | 1,376,388 (-0.2%) | Payment of Exercise Price | |
|
Interim President and CEO
|
Nov 1, 2024 | 9,467 | $10,000 | 1,379,109 (+0.7%) | Exercise/Conversion |